Retinal Toxicity Associated with Nab-Paclitaxel and Gemcitabine with SBP-101
These cases highlight retinal toxicity of the clinical trial drug nab-paclitaxel and gemcitabine with SBP-101 and the need to monitor these patients with regular ophthalmology examinations.
Authors
- Stephen H. Tsang (ORCID: https://orcid.org/0000-0001-9082-2427)
- Vlad Diaconita (ORCID: https://orcid.org/0000-0002-3183-5364)
- Jason Horowitz (ORCID: https://orcid.org/0000-0003-1168-4922)
- Jin Kyun Oh (ORCID: https://orcid.org/0000-0002-5350-9412)
- Aiping Zhou (ORCID: https://orcid.org/0000-0002-3732-7352)
Institutions
- Columbia University Irving Medical Center (US)
- Columbia University (US)
Publication Details
- Journal
- Retinal Cases & Brief Reports
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1097/icb.0000000000001767
- Citations
- 2
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 2.09